Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks

The Lancet Commission on pollution and health

(2018) Philip J Landrigan et al.   LANCET

Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand

(2017) D.T.S. Hayman et al.   VACCINE

Moving beyond traditional valuation of vaccination: Needs and opportunities

(2017) David E. Bloom et al.   VACCINE

Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011–20

(2016) Sachiko Ozawa et al.   HEALTH AFFAIRS

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The fatality and morbidity components of the value of statistical life

(2016) Elissa Philip Gentry et al.   JOURNAL OF HEALTH ECONOMICS

The broader economic impact of vaccination: reviewing and appraising the strength of evidence

(2015) Mark Jit et al.   BMC Medicine

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

(2015) M. Jit et al.   BMJ-British Medical Journal

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

(2015) M. Jit et al.   BMJ-British Medical Journal

Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development

(2015) Benjarin Santatiwongchai et al.   PLoS One

Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009

(2014) F. Zhou et al.   PEDIATRICS

Valuing vaccines using value of statistical life measures

(2014) Ramanan Laxminarayan et al.   VACCINE

ASSESSING WHETHER THERE IS A CANCER PREMIUM FOR THE VALUE OF A STATISTICAL LIFE

(2013) W. Kip Viscusi et al.   HEALTH ECONOMICS

Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact

(2013) Hannah Christensen et al.   VACCINE

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review

(2013) Michaela Fesenfeld et al.   VACCINE

The Cost Effectiveness of Human Papillomavirus Vaccines

(2012) Katherine Seto et al.   DRUGS

Global Burden of Human Papillomavirus and Related Diseases

(2012) David Forman et al.   VACCINE

Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review

(2012) Sachiko Ozawa et al.   VACCINE

QUALITY OF LIFE, TREATMENTS, AND PATIENTS' WILLINGNESS TO PAY FOR A COMPLETE REMISSION OF CERVICAL CANCER IN TAIWAN

(2011) Hui-Chu Lang et al.   HEALTH ECONOMICS

Costs and financial feasibility of malaria elimination

(2010) Oliver Sabot et al.   LANCET

Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine☆

(2010) Till Bärnighausen et al.   VACCINE

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

(2009) Takeru Shiroiwa et al.   HEALTH ECONOMICS

Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine

(2009) Fawziah Marra et al.   PHARMACOECONOMICS

Cost Effectiveness in Low- and Middle-Income Countries

(2009) Samuel D. Shillcutt et al.   PHARMACOECONOMICS